Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/14404
下载链接
链接失效反馈官方服务：
资源简介：
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
创建时间：
2023-05-15
